# Bioequivalence of Telmisartan / Ramipril Fixed Dose Combination Compared With the Monocomponents Given Concomitantly to Healthy Male and Female Volunteers

> **NCT02214979** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 84 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Telmisartan/Ramipril
- **DRUG:** Telmisartan
- **DRUG:** Ramipril capsule
- **DRUG:** Ramipril tablet

## Key facts

- **NCT ID:** NCT02214979
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2007-06
- **Final completion:** —
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2014-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02214979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02214979, "Bioequivalence of Telmisartan / Ramipril Fixed Dose Combination Compared With the Monocomponents Given Concomitantly to Healthy Male and Female Volunteers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02214979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*